IMO an easy comparison to RAP could be made to show just how undervalued we are, RAP sits at $130mil cap with barely any revenue and we sit at $60mil cap with millions more in revenue that is growing.
UCM covers the whole mobile coughing/asthma/COPD market in their own way too as just one portion of the business.
coronavirus is a great way for the company to have the spotlight on it, but as Rob states, this is actually only a fraction of the market we can serve
“Our products address diseases responsible for 75 per cent of the world’s mortalities: heart failure, sepsis, hypertension, asthma and [chronic obstructive pulmonary disease],” Professor Rob Phillips says.“This is stuff that the world spends billions on.”
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.759M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 46000 | 1 |
View Market Depth
| Last trade - 16.21pm 27/06/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable